S Garcia-Ptacek1, M Eriksdotter2, V Jelic2, J Porta-Etessam3, I Kåreholt4, S Manzano Palomo5. 1. Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España; Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Estocolmo, Suecia. Electronic address: saragptacek@gmail.com. 2. Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Estocolmo, Suecia; Department of Geriatric Medicine, Karolinska University Hospital, Karolinska Institutet/Stockholm University, Estocolomo, Suecia. 3. Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España. 4. Aging Research Center, Karolinska Institutet and Stockholm University, Estocolmo, Suecia; Institute of Gerontology, School of Health Sciences, Jönköping University, Jönköping, Suecia. 5. Servicio de Neurología, Hospital Infanta Cristina, Parla, Madrid, España.
Abstract
INTRODUCTION: Neurodegeneration in Alzheimer disease (AD) begins decades before dementia and patients with mild cognitive impairment (MCI) already demonstrate significant lesion loads. Lack of information about the early pathophysiology in AD complicates the search for therapeutic strategies.Subjective cognitive impairment is the description given to subjects who have memory-related complaints without pathological results on neuropsychological tests. There is no consensus regarding this heterogeneous syndrome, but at least some of these patients may represent the earliest stage in AD. METHOD: We reviewed available literature in order to summarise current knowledge on subjective cognitive impairment. RESULTS: Although they may not present detectable signs of disease, SCI patients as a group score lower on neuropsychological tests than the general population does, and they also have a higher incidence of future cognitive decline. Depression and psychiatric co-morbidity play a role but cannot account for all cognitive complaints. Magnetic resonance imaging studies in these patients reveal a pattern of hippocampal atrophy similar to that of amnestic mild cognitive impairment and functional MRI shows increased activation during cognitive tasks which might indicate compensation for loss of function. Prevalence of an AD-like pattern of beta-amyloid (Aβ42) and tau proteins in cerebrospinal fluid is higher in SCI patients than in the general population. CONCLUSIONS: Memory complaints are relevant symptoms and may predict AD. Interpatient variability and methodological differences between clinical studies make it difficult to assign a definition to this syndrome. In the future, having a standard definition and longitudinal studies with sufficient follow-up times and an emphasis on quantifiable variables may clarify aspects of early AD.
INTRODUCTION:Neurodegeneration in Alzheimer disease (AD) begins decades before dementia and patients with mild cognitive impairment (MCI) already demonstrate significant lesion loads. Lack of information about the early pathophysiology in AD complicates the search for therapeutic strategies.Subjective cognitive impairment is the description given to subjects who have memory-related complaints without pathological results on neuropsychological tests. There is no consensus regarding this heterogeneous syndrome, but at least some of these patients may represent the earliest stage in AD. METHOD: We reviewed available literature in order to summarise current knowledge on subjective cognitive impairment. RESULTS: Although they may not present detectable signs of disease, SCI patients as a group score lower on neuropsychological tests than the general population does, and they also have a higher incidence of future cognitive decline. Depression and psychiatric co-morbidity play a role but cannot account for all cognitive complaints. Magnetic resonance imaging studies in these patients reveal a pattern of hippocampal atrophy similar to that of amnestic mild cognitive impairment and functional MRI shows increased activation during cognitive tasks which might indicate compensation for loss of function. Prevalence of an AD-like pattern of beta-amyloid (Aβ42) and tau proteins in cerebrospinal fluid is higher in SCI patients than in the general population. CONCLUSIONS: Memory complaints are relevant symptoms and may predict AD. Interpatient variability and methodological differences between clinical studies make it difficult to assign a definition to this syndrome. In the future, having a standard definition and longitudinal studies with sufficient follow-up times and an emphasis on quantifiable variables may clarify aspects of early AD.
Authors: Alicia D Rueda; Karen M Lau; Naomi Saito; Danielle Harvey; Shannon L Risacher; Paul S Aisen; Ronald C Petersen; Andrew J Saykin; Sarah Tomaszewski Farias Journal: Alzheimers Dement Date: 2014-11-15 Impact factor: 21.566
Authors: Javier Olazarán; Meritxell Valentí; Belén Frades; María Ascensión Zea-Sevilla; Marina Ávila-Villanueva; Miguel Ángel Fernández-Blázquez; Miguel Calero; José Luis Dobato; Juan Antonio Hernández-Tamames; Beatriz León-Salas; Luis Agüera-Ortiz; Jorge López-Álvarez; Pedro Larrañaga; Concha Bielza; Juan Álvarez-Linera; Pablo Martínez-Martín Journal: Front Aging Neurosci Date: 2015-09-30 Impact factor: 5.750
Authors: Hanna Bozkurt Åhman; Vilmantas Giedraitis; Ylva Cedervall; Björn Lennhed; Lars Berglund; Kevin McKee; Lena Kilander; Erik Rosendahl; Martin Ingelsson; Anna Cristina Åberg Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472